Postibrutinib outcomes in patients with mantle cell lymphoma.
about
Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.Gene mutations and actionable genetic lesions in mantle cell lymphoma.CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.From identification of the BTK kinase to effective management of leukemia.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphomaSecond-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.The role of B cell antigen receptors in mantle cell lymphoma.Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.SOX11 augments BCR signaling to drive MCL-like tumor development.First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.The B cell receptor signaling pathway in mantle cell lymphoma.The molecular pathogenesis of mantle cell lymphoma.Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
P2860
Q30248407-BFD29A37-05A3-40D0-9F9A-63AF28C6EB98Q33587128-FB36E2A7-D9C2-413D-8C42-7E33F9F3F643Q37629080-FD588575-0944-49DF-8617-E94528781CFEQ37687430-CA5745B1-ACD7-496D-88EC-1B462503B2E4Q38612385-CADE8A41-2D53-4582-85EA-161278898150Q38665207-BDFD65DE-41DB-4354-89D4-17144605F1A8Q38765458-66CBD517-7CD3-465E-B44B-A45B2CAAB6E9Q38817591-4A18BC1A-121D-4213-BD75-D0F5A8E1E731Q38860997-FD6FD4D3-D4EE-450A-AE07-8C85577D0256Q39045701-D61CAA3E-C4A9-48D6-AD55-F5E0D0C73662Q39325783-5CBBB105-F4A2-46FC-B47B-C0209B096899Q39694093-50B452C7-7144-4904-A7C5-CF5E5001FB1BQ41070355-15C7A44D-716C-4971-8E82-B7D37E095705Q42070740-19D9383E-8D77-423F-A5A3-17BE9CAF46BAQ42336329-4CF483C1-FCA9-462D-ADBB-D56D55E47EC1Q42682371-92B0AB78-E595-4019-8DFF-600EA601345BQ43296855-68BF416B-90B1-4B9E-A8B4-49EEEC2D4F53Q45050435-FEB9AD04-C895-4CA4-BFB5-C669F8900F3DQ47549122-9BF2AE14-E198-4A66-A29E-A5F9DFD61821Q47699487-157B3BDC-0334-4C55-A465-CBCF09A03236Q48238170-CE2D4EBB-1390-4D90-9413-447D9F300B2CQ48298180-BF41A288-9A70-4F1E-95C5-FF88F5C162E8Q48335342-E83962FC-D679-4498-BEC0-CE4890629386Q50042359-7A78EAA0-6281-4C11-837E-FA19FE940E72Q50200754-F64E97B2-29D8-454B-BA2C-44675759F5FAQ52609176-F49CE816-FB15-4B61-A299-55871353B449Q52645845-A506300C-4FE3-4D2C-B2B4-F711C0472049Q54977238-B7D7D90F-C55A-46EE-A3F1-D5EE11EAE589Q55007581-61BCCA41-C32A-479C-96E8-5968240CBF93Q55380607-0EAC0DA9-66FB-4241-90F7-505E8F391ECCQ55504502-B7AC6E97-54C3-4F94-86F8-A470EDAEA1E2Q56514276-80ADB86B-7000-4972-9BDF-3EE2921B3B8F
P2860
Postibrutinib outcomes in patients with mantle cell lymphoma.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Postibrutinib outcomes in patients with mantle cell lymphoma.
@ast
Postibrutinib outcomes in patients with mantle cell lymphoma.
@en
type
label
Postibrutinib outcomes in patients with mantle cell lymphoma.
@ast
Postibrutinib outcomes in patients with mantle cell lymphoma.
@en
prefLabel
Postibrutinib outcomes in patients with mantle cell lymphoma.
@ast
Postibrutinib outcomes in patients with mantle cell lymphoma.
@en
P2093
P50
P1433
P1476
Postibrutinib outcomes in patients with mantle cell lymphoma.
@en
P2093
David Iberri
Eliana Kozin
Ewa Chmielowska
Johannes Bloehdorn
John P Leonard
Kami Maddocks
Katherine Noto
Kristie A Blum
P304
P356
10.1182/BLOOD-2015-10-673145
P407
P577
2016-01-13T00:00:00Z